Analytical advances in horseracing medication and doping control from 2018 to 2023.

1. Scarth J, McKinney A, Bailly‐Chouriberry L, et al. Analytical Advances in horseracing medication and doping control from 2016 to 2018. In: Proceedings of the 22nd International Conference of Racing Analysts and Veterinarians, Dubai; 2018:74‐88.
2. Tozaki T, Ohnuma A, Kikuchi M, et al. Microfluidic quantitative PCR detection of 12 transgenes from horse plasma for gene doping control. Genes (Basel). 2020;11(4):457.
3. Cantelmo RA, da Silva AP, Mendes‐Junior CT, Dorta DJ. Gene doping: present and future. Eur J Sport Sci. 2020;20(8):1093‐1101.
4. Campbell M. Ethics, genetic technologies and equine sports. Equine Vet J. 2020;52(6):893.
5. Tozaki T, Hamilton NA. Control of gene doping in human and horse sports. Gene Ther. 2022;29(3‐4):107‐112.
6. Lu Y, Yan J, Ou G, Fu L. A review of recent Progress in drug doping and gene doping control analysis. Molecules. 2023;28(14):5483.
7. Cheung HW, Wong KS, Lin VYC, Wan TSM, Ho ENM. A duplex qPCR assay for human erythropoietin (EPO) transgene to control gene doping in horses. Drug Test Anal. 2021;13(1):113‐121.
8. Maniego J, Pesko B, Hincks P, et al. Direct sequence confirmation of qPCR products for gene doping assay validation in horses. Drug Test Anal. 2022;14(6):1017‐1025.
9. Jiang Z, Haughan J, Moss KL, Stefanovski D, Ortved KF, Robinson MA. A quantitative PCR screening method for adeno‐associated viral vector 2‐mediated gene doping. Drug Test Anal. 2022;14(5):963‐972.
10. Tozaki T, Gamo S, Takasu M, et al. Digital PCR detection of plasmid DNA administered to the skeletal muscle of a microminipig: a model case study for gene doping detection. BMC Res Notes. 2018;11(1):708.
11. Tozaki T, Ohnuma A, Takasu M, et al. Droplet digital PCR detection of the erythropoietin transgene from horse plasma and urine for gene‐doping control. Genes (Basel). 2019;10(3):243.
12. O'Hara V, Cowan A, Riddell D, Massey C, Martin J, Piercy RJ. A highly prevalent SINE mutation in the myostatin (MSTN) gene promoter is associated with low circulating myostatin concentration in thoroughbred racehorses. Sci Rep. 2021;11(1):7916.
13. Littiere TO, Castro GHF, Rodriguez M.DP.R, et al. Identification and functional annotation of genes related to Horses' performance: from GWAS to post‐GWAS. Animals. 2020;10(7):1173. doi:10.3390/ani10071173
14. Han H, McGivney BA, Allen L, et al. Common protein‐coding variants influence the racing phenotype in galloping racehorse breeds. Commun Biol. 2022;5(1):1320.
15. Holtby AR, Hall TJ, McGivney BA, et al. Integrative genomics analysis highlights functionally relevant genes for equine behaviour. Anim Genet. 2023;54(4):457‐469.
16. Fontanel M, Todd E, Drabbe A, et al. Variation in the SLC16A1 and the ACOX1 genes is associated with gallop racing performance in Arabian horses. J Equine Vet. 2020;93:103202.
17. Velie BD, Fegraeus KJ, Solé M, et al. A genome‐wide association study for harness racing success in the Norwegian‐Swedish coldblooded trotter reveals genes for learning and energy metabolism. BMC Genet. 2018;19(1):80.
18. Maniego J, Pesko B, Habershon‐Butcher J, et al. Screening for gene doping transgenes in horses via the use of massively parallel sequencing. Gene Ther. 2022;29(5):236‐246.
19. Wong KS, Cheung HW, Szeto CWL, Tsang CYN, Wan TSM, Ho ENM. A multiplex qPCR assay for transgenes detection ‐ a novel approach for gene doping control in horseracing using conventional laboratory setup. Drug Test Anal. 2023;15(8):879‐888.
20. Ohnuma A, Tozaki T, Kikuchi M, et al. Multiplex detection of transgenes using πCode technology for gene doping control. Anal Chem. 2023;95(27):10149‐10154.
21. Tozaki T, Ohnuma A, Kikuchi M, et al. Identification of processed pseudogenes in the genome of thoroughbred horses: possibility of gene‐doping detection considering the presence of pseudogenes. Anim Genet. 2022;53(2):183‐192.
22. Tozaki T, Ohnuma A, Iwai S, et al. Robustness of digital PCR and real‐time PCR in transgene detection for gene‐doping control. Anal Chem. 2021;93(18):7133‐7139.
23. Tozaki T, Ohnuma A, Kikuchi M, et al. Robustness of digital PCR and real‐time PCR against inhibitors in transgene detection for gene doping control in equestrian sports. Drug Test Anal. 2021;13(10):1768‐1775.
24. Tozaki T, Ohnuma A, Kikuchi M, et al. Design and storage stability of reference materials for microfluidic quantitative PCR‐based equine gene doping tests. J Equine Sci. 2021;32(4):125‐134.
25. Tozaki T, Ohnuma A, Kikuchi M, et al. Investigation of optimal procedures for storage and use of plasma samples suitable for gene doping tests. J Equine Sci. 2023;34(2):21‐27.
26. Maniego J, Pesko B, Habershon‐Butcher J, et al. Detection of adeno‐associated viral DNA in equine post‐administration frozen blood and plasma samples after long term storage. Drug Test Anal. 2023;16(5):498‐503.
27. Tozaki T, Ohnuma A, Hamilton NA, et al. Low‐copy transgene detection using nested digital polymerase chain reaction for gene‐doping control. Drug Test Anal. 2022;14(2):382‐387.
28. Haughan J, Jiang Z, Stefanovski D, Moss KL, Ortved KF, Robinson MA. Detection of intra‐articular gene therapy in horses using quantitative real time PCR in synovial fluid and plasma. Drug Test Anal. 2020;12(6):743‐751.
29. Cheung HW, Wong KS, Lin VYC, et al. Optimization and implementation of four duplex quantitative polymerase chain reaction assays for gene doping control in horseracing. Drug Test Anal. 2022;14(9):1587‐1598.
30. Haughan J, Ortved KF, Robinson MA. Administration and detection of gene therapy in horses: a systematic review. Drug Test Anal. 2023;15(2):143‐162.
31. Tozaki T, Ohnuma A, Kikuchi M, et al. Simulated validation of intron‐less transgene detection using DELLY for gene‐doping control in horse sports. Anim Genet. 2021;52(5):759‐761.
32. Tozaki T, Ohnuma A, Takasu M, et al. Detection of non‐targeted transgenes by whole‐genome resequencing for gene‐doping control. Gene Ther. 2021;28(3‐4):199‐205.
33. Pinzon‐Arteaga C, Snyder MD, Lazzarotto CR, et al. Efficient correction of a deleterious point mutation in primary horse fibroblasts with CRISPR‐Cas9. Sci Rep. 2020;10(1):7411.
34. Moro LN, Viale DL, Bastón JI, et al. Generation of myostatin edited horse embryos using CRISPR/Cas9 technology and somatic cell nuclear transfer. Sci Rep. 2020;10(1):15587.
35. Tozaki T, Ohnuma A, Kikuchi M, et al. Rare and common variant discovery by whole‐genome sequencing of 101 thoroughbred racehorses. Sci Rep. 2021;11(1):16057.
36. Tozaki T, Ohnuma A, Kikuchi M, et al. Short insertion and deletion discoveries via whole‐genome sequencing of 101 thoroughbred racehorses. Genes (Basel). 2023;14(3):638.
37. Tozaki T, Ohnuma A, Nakamura K, et al. Detection of indiscriminate genetic manipulation in thoroughbred racehorses by targeted resequencing for gene‐doping control. Genes (Basel). 2022;13(9):1589.
38. Maniego J, Giles O, Hincks P, Stewart G, Proudman C, Ryder E. Long‐read sequencing assays designed to detect potential gene editing events in the myostatin gene revealed distinct haplotype signatures in the thoroughbred horse population. Anim Genet. 2023;54(4):470‐482.
39. Maniego J, Pesko B, Habershon‐Butcher J, et al. Use of mitochondrial sequencing to detect gene doping in horses via gene editing and somatic cell nuclear transfer. Drug Test Anal. 2022;14(8):1429‐1437.
40. Tozaki T, Ohnuma A, Kikuchi M, et al. Whole‐genome resequencing using genomic DNA extracted from horsehair roots for gene‐doping control in horse sports. J Equine Sci. 2020;31(4):75‐83. doi:10.1294/jes.31.75
41. Dahlgren AR, Knych HK, Arthur RM, Durbin‐Johnson BP, Finno CJ. Transcriptomic markers of recombinant human erythropoietin micro‐dosing in thoroughbred horses. Genes (Basel). 2021;12(12):1874.
42. Loup B, André F, Avignon J, et al. miRNAs detection in equine plasma by quantitative polymerase chain reaction for doping control: assessment of blood sampling and study of eca‐miR‐144 as potential erythropoiesis stimulating agent biomarker. Drug Test Anal. 2022;14(5):953‐962.
43. Jiang Z, Chen JW, Haughan J, Stefanovski D, Soma LR, Robinson MA. Gene transcripts expressed in equine white blood cells are potential biomarkers of extracorporeal shock wave therapy. Drug Test Anal. 2022;14(5):973‐982.
44. Tozaki T, Karasawa K, Minamijima Y, et al. Detection of phosphorothioated (PS) oligonucleotides in horse plasma using a product ion (m/z 94.9362) derived from the PS moiety for doping control. BMC Res Notes. 2018;11(1):770.
45. Tozaki T, Kwak HG, Nakamura K, et al. Sequence determination of phosphorothioated oligonucleotides using MALDI‐TOF mass spectrometry for controlling gene doping in equestrian sports. Drug Test Anal. 2022;14(1):175‐180.
46. Genangeli M, Caprioli G, Cortese M, et al. Simultaneous quantitation of 9 anabolic and natural steroidal hormones in equine urine by UHPLC‐MS/MS triple quadrupole. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1117:36‐40.
47. Caprioli G, Genangeli M, Mustafa AM, et al. Quantification of 17 endogenous and exogenous steroidal hormones in equine and bovine blood for doping control with UHPLC‐MS/MS. Pharmaceuticals (Basel). 2021;14(5):393.
48. Delcourt V, Garcia P, Pottier I, et al. Development of a standardized microflow LC gradient to enable sensitive and long‐term detection of synthetic anabolic‐androgenic steroids for high‐throughput doping controls. Anal Chem. 2021;93(47):15590‐15596.
49. Waller CC, Weththasinghe SA, McClure L, et al. In vivo metabolism of the designer anabolic steroid hemapolin in the thoroughbred horse. Drug Test Anal. 2020;12(6):752‐762.
50. Harding C, Viljanto M, Cutler C, Habershon‐Butcher J, Biddle S, Scarth J. In vitro and in vivo metabolism of the anabolic‐androgenic steroid oxandrolone in the horse. Drug Test Anal. 2022;14(1):39‐55.
51. Weththasinghe SA, Waller CC, Fam HL, Stevenson BJ, Cawley AT, McLeod MD. Replacing PAPS: in vitro phase II sulfation of steroids with the liver S9 fraction employing ATP and sodium sulfate. Drug Test Anal. 2018;10(2):330‐339.
52. Viljanto M, Pita CH, Scarth J, Walker CJ, Kicman AT, Parkin MC. Important considerations for the utilisation of methanolysis in steroid analysis. Drug Test Anal. 2018;10(9):1469‐1473.
53. Kollmeier AS, Parr MK. Mass spectral fragmentation analyses of isotopically labelled hydroxy steroids using gas chromatography/electron ionization low‐resolution mass spectrometry: a practical approach. Rapid Commun Mass Spectrom. 2020;34(12):e8769.
54. Fitzgerald CCJ, Hedman R, Uduwela DR, et al. Profiling urinary sulfate metabolites with mass spectrometry. Front Mol Biosci. 2022;9:829511.
55. Fitzgerald CCJ, Bowen C, Elbourne M, Cawley A, McLeod MD. Energy‐resolved fragmentation aiding the structure elucidation of steroid biomarkers. J am Soc Mass Spectrom. 2022;33(7):1276‐1281.
56. Lund RA, Cooper ER, Wang H, Ashley Z, Cawley AT, Heather AK. Nontargeted detection of designer androgens: underestimated role of in vitro bioassays. Drug Test Anal. 2021;13(5):894‐902.
57. Gillon A, Ho ENM, Chan GHM, et al. Unravelling androgens in sport: Altrenogest shows strong activation of the androgen receptor in a mammalian cell bioassay. Drug Test Anal. 2021;13(3):523‐528.
58. Cooper ER, Hughes G, Kauff A, Sutherland E, Ashley Z, Heather AK. A cell‐free bioassay for the detection of androgens. Drug Test Anal. 2021;13(5):903‐915. Erratum in: Drug Test Anal. 2022 14(1):196
59. Broberg MN, Knych H, Bondesson U, et al. Investigation of equine in vivo and in vitro derived metabolites of the selective androgen receptor modulator (SARM) ACP‐105 for improved doping control. Metabolites. 2021;11(2):85.
60. Subhahar MB, Karakka Kal AK, Philip M, et al. Detection and identification of ACP‐105 and its metabolites in equine urine using LC/MS/MS after oral administration. Drug Test Anal. 2021;13(2):299‐317.
61. Cutler C, Viljanto M, Hincks P, Habershon‐Butcher J, Muir T, Biddle S. Investigation of the metabolism of the selective androgen receptor modulator LGD‐4033 in equine urine, plasma and hair following oral administration. Drug Test Anal. 2020;12(2):247‐260.
62. Cutler C, Viljanto M, Taylor P, et al. Equine metabolism of the selective androgen receptor modulator AC‐262536 in vitro and in urine, plasma and hair following oral administration. Drug Test Anal. 2021;13(2):369‐385.
63. Harding C, Viljanto M, Habershon‐Butcher J, Taylor P, Scarth J. Equine metabolism of the selective androgen receptor modulator YK‐11 in urine and plasma following oral administration. Drug Test Anal. 2023;15(4):388‐407.
64. Karatt TK, Sathiq MA, Laya S, et al. Metabolic study of selective androgen receptor modulator LY2452473 in thoroughbred horses for doping control. Rapid Commun Mass Spectrom. 2023;37(9):e9491.
65. Karatt TK, Sathiq MA, Laya S, et al. In‐depth metabolic study of nonsteroidal selective androgen receptor modulator GSK2881078 in thoroughbred horses and horse liver microsomes for doping control. Drug Test Anal. 2023;15(7):757‐768.
66. Karatt TK, Sathiq MA, Laya S, Philip M, Karakka Kal AK, Subhahar MB. Investigation of in vitro generated metabolites of GLPG0492 using equine liver microsomes for doping control. Drug Test Anal. 2023;15(6):605‐628.
67. So YM, Wong JKY, Choi TLS, et al. Metabolic studies of selective androgen receptor modulators RAD140 and S‐23 in horses. Drug Test Anal. 2021;13(2):318‐337.
68. Ventura E, Gadaj A, Monteith G, et al. Development and validation of a semi‐quantitative ultra‐high performance liquid chromatography‐tandem mass spectrometry method for screening of selective androgen receptor modulators in urine. J Chromatogr A. 2019;1600:183‐196.
69. Ventura E, Gadaj A, Buckley T, Mooney MH. Development of a multi‐residue high‐throughput UHPLC‐MS/MS method for routine monitoring of SARM compounds in equine and bovine blood. Drug Test Anal. 2020;12(9):1373‐1379.
70. Gadaj A, Ventura E, Healy J, et al. Enhanced UHPLC‐MS/MS screening of selective androgen receptor modulators following urine hydrolysis. MethodsX. 2020;7:100926.
71. Ventura E, Gadaj A, Buckley T, Mooney MH. Investigation of stability of selective androgen receptor modulators in urine. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2020;37(8):1253‐1263.
72. Cutler C, Viljanto M, Taylor P, Hincks P, Biddle S, Van Eenoo P. Identification of equine in vitro metabolites of seven non‐steroidal selective androgen receptor modulators for doping control purposes. Drug Test Anal. 2022;14(2):349‐370.
73. Philip M, Mathew B, Karatt TK, Perwad Z, Subhahar MB, Karakka Kal AK. Metabolic studies of hypoxia‐inducible factor stabilisers IOX2, IOX3 and IOX4 (in vitro) for doping control. Drug Test Anal. 2021;13(4):794‐816.
74. Ishii H, Shibuya M, So YM, et al. Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high‐resolution mass spectrometer for the purpose of doping control. Drug Test Anal. 2022;14(2):233‐251.
75. Philip M, Karakka Kal AK, Subhahar MB, Karatt TK, Mathew B, Perwad Z. In vitro studies of hypoxia inducible factor‐prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control. Drug Test Anal. 2021;14(2):317‐348.
76. Ishii H, Shibuya M, Kusano K, et al. Pharmacokinetic study of Vadadustat and high‐resolution mass spectrometric characterization of its novel metabolites in equines for the purpose of doping control. Curr Drug Metab. 2022;23(10):850‐865. doi:10.2174/1389200223666220825093945
77. Mathew B, Philip M, Perwad Z, et al. Identification of hypoxia‐inducible factor (HIF) stabilizer roxadustat and its possible metabolites in thoroughbred horses for doping control. Drug Test Anal. 2021;13(6):1203‐1215.
78. Mikhail E, Siccardi E, Bawazir A, et al. A validated method for the quantification of IOX‐2, a potent prolyl hydroxylase inhibitor in equine urine and plasma using liquid chromatography‐high‐resolution mass spectrometry. Drug Test Anal. 2021;13(6):1178‐1190.
79. Philip M, Karakka Kal AK, Mathew B, Subhahar MB, Karatt TK, Perwad Z. Metabolic study of hypoxia‐inducible factor stabilizers BAY 87‐2243, MK‐8617, and PT‐2385 in equine liver microsomes for doping control. Drug Test Anal. 2022;14(10):1703‐1723.
80. Cutler C, White DL, Viljanto M. In vitro metabolism of the REV‐ERB agonist SR‐9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples. Drug Test Anal. 2022;14(1):169‐174.
81. Kwak YB, Yu J, Yoo HH. A quantitative method for the simultaneous detection of SR9009 and SR9011 in equine plasma using liquid chromatography‐electrospray ionization‐tandem mass spectrometry. Drug Test Anal. 2022;14(8):1532‐1538.
82. Ishii H, Leung GN, Yamashita S, et al. Doping control analysis of GW1516 in equine plasma using liquid chromatography/electrospray ionization Q‐Exactive high‐resolution mass spectrometry. Rapid Commun Mass Spectrom. 2020;34(23):e8920.
83. Ishii H, Shibuya M, Leung GN, et al. Metabolic study of GW1516 in equine urine using liquid chromatography/electrospray ionization Q‐Exactive high‐resolution mass spectrometry for doping control. Rapid Commun Mass Spectrom. 2021;35(5):e9028.
84. Trevisiol S, Moulard Y, Delcourt V, et al. Comprehensive characterization of the peroxisome proliferator activated receptor‐δ agonist GW501516 for horse doping control analysis. Drug Test Anal. 2021;13(6):1191‐1202.
85. Cutler C, Viljanto M, Taylor P, Habershon‐Butcher J, Van Eenoo P. Equine metabolism of the growth hormone secretagogue MK‐0677 in vitro and in urine and plasma following oral administration. Drug Test Anal. 2022;14(7):1273‐1290.
86. Philip M, Karakka Kal AK, Subhahar MB, Perwad Z, Karatt TK. Characterization of equine liver microsome‐generated metabolites of growth hormone secretagogue small molecule ibutamoren. Rapid Commun Mass Spectrom. 2021;35(23):e9201.
87. Philip M, Karakka Kal AK, Subhahar MB, Karatt TK, Mathew B, Koshy SA. Characterization of growth hormone secretagogue small molecule ibutamoren (MK‐0677) and its possible metabolites in thoroughbred horses for doping control. Rapid Commun Mass Spectrom. 2022;36(18):e9337.
88. Karatt TK, Sayed R, Nalakath J, Perwad Z, Albert PH, Abdul Khader KK. Separation and identification of the epimeric doping agents ‐ dexamethasone and betamethasone in equine urine and plasma: a reversed phase chiral chromatographic approach. Steroids. 2018;140:77‐82.
89. Karatt TK, Sathiq MA, Laya S. Is 9β‐dehydrohalogenation of betamethasone and dexamethasone hindering the detection of banned co‐eluting meprednisone? A reverse‐phase chiral liquid chromatography high‐resolution mass spectrometry approach. Steroids. 2020;155:108572.
90. Trevisiol S, Moulard Y, Kaabia Z, et al. LC‐HRMS/MS study of the prodrug ciclesonide and its active metabolite desisobutyryl‐ciclesonide in plasma after an inhalative administration to horses for doping control purposes. Drug Test Anal. 2022;14(2):252‐261.
91. Kikuchi M, Nagata SI, Ishige T, et al. Evaluation of the effect of glucocorticoid treatment on adrenocortical functions by monitoring endogenous hydrocortisone in horses. J Vet Med Sci. 2023;85(6):647‐652.
92. Stucki M, Voegel CD, Binz TM, Kraemer T, Lavaud A, Voelter K. Systemic detectability of dexamethasone and prednisolone after eye drop application in horses. Equine Vet J. 2021;53(6):1250‐1256.
93. Wong JKY, Choi TLS, Kwok KY, Lei ENY, Wan TSM. Doping control analysis of 121 prohibited substances in equine hair by liquid chromatography‐tandem mass spectrometry. J Pharm Biomed Anal. 2018;158:189‐203.
94. Choi TLS, Kwok KY, Kwok WH, Tsoi YYK, Wong JKY, Wan TSM. Detection of seventy‐two anabolic and androgenic steroids and/or their esters in horse hair using ultra‐high performance liquid chromatography‐high resolution mass spectrometry in multiplexed targeted MS2 mode and gas chromatography‐tandem mass spectrometry. J Chromatogr a. 2018;1566:51‐63.
95. Ishii H, Shibuya M, So YM, et al. Long‐term monitoring of IOX4 in horse hair and its longitudinal distribution with segmental analysis using liquid chromatography/electrospray ionization Q Exactive high‐resolution mass spectrometry for the purpose of doping control. Drug Test Anal. 2022;14(7):1244‐1254.
96. Ishii H, Shibuya M, Kusano K, et al. First evidence of the incorporation of daprodustat and other hypoxia‐inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis. J Pharm Biomed Anal. 2023;235:115600.
97. Moeller BC, Clifford A, Emery RT, Alarcio G, Favro G, Arthur RM. Detection and confirmation of zilpaterol in equine hair using liquid chromatography‐mass spectrometry. Drug Test Anal. 2022;14(1):31‐38.
98. Viljanto M, Cutler C, Taylor P, Habershon‐Butcher J, Gray B. Detection of the growth hormone secretagogue MK‐0677 in equine hair following oral administration. Drug Test Anal. 2022;15(3, 367):361.
99. Moeller BC, Flores L, Clifford A, Alarcio G, Mosburg M, Arthur RM. Detection of methylphenidate in equine hair using liquid chromatography‐high‐resolution mass spectrometry. Molecules. 2021;26(19):5798. doi:10.3390/molecules26195798
100. Ishii H, Shibuya M, Leung GN, et al. Detection and longitudinal distribution of GW1516 and its metabolites in equine hair for doping control using liquid chromatography/high‐resolution mass spectrometry. Rapid Commun Mass Spectrom. 2021;35(8):e9050.
101. Knych HK, McKemie DS, Yim S, Stanley SD, Arthur RM. Long‐term monitoring of clodronate in equine hair using liquid chromatography‐tandem mass spectrometry. J Chrom B Online epub. 2023;1226:123789. doi:10.1016/j.jchromb.2023.123789
102. Moeller BC, Yang Z. Evaluation of dried blood spots as an alternative sample matrix for equine antidoping analysis. Drug Test Anal. 2021;13(2):386‐396.
103. Lange T, Thomas A, Walpurgis K, Thevis M. Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non‐peptide doping agents by means of LC‐HRMS. Anal Bioanal Chem. 2020;412(15):3765‐3777. doi:10.1007/s00216‐020‐02634‐4
104. Samsonova JV, Saushkin NY, Osipov AP. Dried blood spots technology for veterinary applications and biological investigations: technical aspects, retrospective analysis, ongoing status and future perspectives. Vet Res Commun. 2022;46(3):655‐698. doi:10.1007/s11259‐022‐09957‐w
105. Lerch M, Allbaugh RA, Sebbag L, Mochel JP, Weller P, Borts DJ. Paper spray high‐resolution accurate mass spectrometry for quantitation of voriconazole in equine tears. Anal Bioanal Chem. 2019;411(20):5187‐5196. doi:10.1007/s00216‐019‐01898‐9
106. Chan GHM, Tang W, Curl P, Lin Y, Wan TSM, Ho ENM. Doping control analysis of total arsenic in equine plasma. Drug Test Anal. 2020;12(10):1462‐1469.
107. Kwak YB, Yu J, Im EJ, Jeong BS, Yoo HH. Study of cobalt doping control via various routes in thoroughbred horses. Drug Test Anal. 2022;14(4):718‐723.
108. Schumacher SA, Yardley J, Bertone AL. Ionized magnesium and calcium concentration and their ratio in equine plasma samples as determined by a regulatory laboratory compared to a clinical reference laboratory. Drug Test Anal. 2019;11(3):455‐460.
109. Fazio F, Gugliandolo E, Nava V, Piccione G, Giannetto C, Licata P. Bioaccumulation of mineral elements in different biological substrates of athletic horse from Messina, Italy. Animals (Basel). 2020;10(10):1877.
110. Fazio F, Aragona F, Piccione G, Arfuso F, Giannetto C. Lithium concentration in biological samples and gender difference in athletic horses. J Equine Vet. 2022;117:104081.
111. Giannetto C, Fazio F, Nava V, et al. Data on multiple regression analysis between boron, nickel, arsenic, antimony, and biological substrates in horses: the role of hematological biomarkers. J Biochem Mol Toxicol. 2022;36(2):e22955.
112. Karakka Kal AK, Perwad Z, Karatt TK, Nalakath J, Subhahar M. Using inductively coupled plasma mass spectrometry to assess essential and performance‐enhancing metals in the urine of racehorses. J Anal Toxicol. 2020;44(5):490‐498.
113. Davis JL, Schirmer J, Medlin E. Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m‐chlorophenylpiperazine in the horse. J Vet Pharmacol Ther. 2018;41(3):393‐401.
114. Knych HK, McKemie DS, Seminoff K, Hartmann P, Hovda L, Benson D. L‐ and D‐threo ethylphenidate concentrations, pharmacokinetics, and pharmacodynamics in horses. Drug Test Anal. 2018;10(10):1508‐1517.
115. Knych HK, Seminoff K, McKemie DS. Detection and pharmacokinetics of grapiprant following oral administration to exercised thoroughbred horses. Drug Test Anal. 2018;10(8):1237‐1243.
116. Hoffmann SL, Seminoff K, McKemie DS, Kass PH, Knych HK. Pharmacokinetics of grapiprant and effects on TNF‐alpha concentrations following oral administration to horses. J Vet Pharmacol Ther. 2022;45(5):467‐472.
117. Martin EM, Schirmer JM, Jones SL, Davis JL. Pharmacokinetics and ex vivo anti‐inflammatory effects of oral misoprostol in horses. Equine Vet J. 2019;51(3):415‐421.
118. Soma LR, You Y, Robinson MA, Boston RC. Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3‐hydroxylidocaine, monoethylglycinexylidide, and 4‐hydroxylidocaine in horse. J Vet Pharmacol Ther. 2018;41(6):825‐837.
119. Soma LR, Robinson MA, You Y, Boston RC, Rudy J. Pharmacokinetics, disposition, and plasma concentrations of dimethyl sulfoxide (DMSO) in the horse following topical, oral, and intravenous administration. J Vet Pharmacol Ther. 2018;41(3):384‐392.
120. Waraksa E, Wójtowicz‐Zawadka M, Kwiatkowska D, et al. Simultaneous determination of ibuprofen and its metabolites in complex equine urine matrices by GC‐EI‐MS in excretion study in view of doping control. J Pharm Biomed Anal. 2018;152:279‐288.
121. Axmann S, Hummel K, Nobauer K, Razzazi‐Fazeli E, Zitterl‐Eglseer K. Pharmacokinetics of harpagoside in horses after intragastric administration of a devil's claw (Harpagophytum procumbens) extract. J Vet Pharmacol Ther. 2019;42(1):37‐44. doi:10.1111/jvp.12716
122. Berryhill EH, Knych H, Edman JM, Magdesian KG. Pharmacokinetics of single doses of maropitant citrate in adult horses. J Vet Pharmacol Ther. 2019;42(4):487‐491.
123. Berryhill EH, Knych H, Chigerwe M, Edman J, Magdesian KG. Pharmacokinetics of maropitant citrate after oral administration of multiple doses in adult horses. J Vet Pharmacol Ther. 2020;43(3):282‐287.
124. Dahan R, Oreff GL, Tatz AJ, Raz T, Britzi M, Kelmer G. Pharmacokinetics of regional limb perfusion using a combination of amikacin and penicillin in standing horses. Can Vet J. 2019;60(3):294‐299.
125. Gajardo G, López‐Muñoz R, Plaza A, et al. Tamoxifen in horses: pharmacokinetics and safety study. Ir Vet J. 2019;72:5.
126. Gozalo‐Marcilla M, Luna SPL, Moreira da Silva R, et al. Characterisation of the in vivo interactions between detomidine and methadone in horses: pharmacokinetic and pharmacodynamic modelling. Equine Vet J. 2019;51(4):517‐529.
127. Hamamoto‐Hardman BD, Steffey EP, Weiner D, McKemie DS, Kass P, Knych HK. Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses. J Vet Pharmacol Ther. 2019;42(4):401‐410.
128. Poth MKM, McKemie DS, Traynham M, Kass PH, Knych HK. Concentrations, pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites following oral administration to horses. J Vet Pharmacol Ther. 2023;46(4):238‐249.
129. Knych HK, Arthur RM, Kanarr KL, McKemie DS, Kass PH. Detection, pharmacokinetics, and selected pharmacodynamic effects of methamphetamine following a single transmucosal and intravenous administration to exercised thoroughbred horses. Drug Test Anal. 2019;11(9):1431‐1443.
130. Knych HK, Arthur RM, McKemie DS, Seminoff K, Hamamoto‐Hardman B, Kass PH. Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. Drug Test Anal. 2019;11(6):792‐803.
131. Knych HK, Weiner D, Steinmetz S, Flynn K, McKemie DS. Pharmacokinetics of hydroxyzine and cetirizine following oral administration of hydroxyzine to exercised thoroughbred horses. J Vet Pharmacol Ther. 2019;42(6):617‐623.
132. Paine SW, Aldurdunji M, Garth‐Greeves A, Muir T, Hincks PR. Plasma and urine pharmacokinetics of hydroxyzine and cetirizine following repeated oral administrations to exercised horses. J Vet Pharmacol Ther. 2022;45(1):46‐53.
133. Knych HK, Arthur RM, McKemie DS, Baden R, Oldberg N, Kass PH. Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. Equine Vet J. 2019;51(2):238‐245.
134. Patel T, Magdesian KG, Estell KE, Edman JM, Knych HK. Pharmacokinetics of chloramphenicol base in horses and comparison to compounded formulations. J Vet Pharmacol Ther. 2019;42(6):609‐616.
135. Estell KE, Knych HK, Patel T, Edman JM, Magdesian KG. Pharmacokinetics of multiple doses of chloramphenicol in fed adult horses. Vet J. 2020;257:105446.
136. Langston VC, Fontenot RL, Byers JA, Andrews CM, Mochal‐King CA. Plasma and synovial fluid pharmacokinetics of a single intravenous dose of meropenem in adult horses. J Vet Pharmacol Ther. 2019;42(5):525‐529.
137. Machin J, Duer W, Maylin G, et al. Variability in plasma concentrations of methylprednisolone 6 days after intrasynovial injection of methylprednisolone acetate in racing horses: a field study. Equine Vet J. 2019;51(3):343‐348.
138. Subhahar MB, Singh J, Albert PH, Kadry AM. Pharmacokinetics, metabolism and excretion of celecoxib, a selective cyclooxygenase‐2 inhibitor, in horses. J Vet Pharmacol Ther. 2019;42(5):518‐524.
139. Villarino NF, Lopez CM, Sams RA, Bayly WM. Pharmacokinetics of furosemide in thoroughbred horses subjected to supramaximal treadmill exercise with and without controlled access to water. BMC Vet Res. 2019;15(1):275.
140. Younkin JT, Santschi EM, Kukanich B, Lubbers BV, Warner M. Evaluation of plasma concentration after intravenous and intramuscular penicillin administration over 24 hr in healthy adult horses. J Vet Pharmacol Ther. 2019;42(2):239‐242.
141. Gretler SR, Finno CJ, McKemie DS, Kass PH, Knych HK. Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. Vet Anaesth Analg. 2020;47(5):694‐704.
142. Gretler SR, Finno CJ, Kass PH, Knych HK. Functional phenotyping of the CYP2D6 probe drug codeine in the horse. BMC Vet Res. 2021;17(1):77.
143. Knych HK, Stucker K, Gretler SR, Kass PH, McKemie DS. Pharmacokinetics, adverse effects and effects on thermal nociception following administration of three doses of codeine to horses. BMC Vet Res. 2022;18(1):196.
144. Guedes A, Knych H, Tucker L, et al. Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. J Vet Pharmacol Ther. 2020;43(4):369‐376.
145. Habershon‐Butcher J, Cutler C, Viljanto M, Hincks PR, Biddle S, Paine SW. Re‐evaluation of the pharmacokinetics of xylazine administered to thoroughbred horses. J Vet Pharmacol Ther. 2020;43(1):6‐12.
146. Hopster K, Soma LR, Li X, Hopster‐Iversen C, Boston RC, Driessen B. Pharmacokinetics of xylazine after 2‐, 4‐, and 6‐hr durations of continuous rate infusions in horses. J Vet Pharmacol Ther. 2020;43(6):557‐564.
147. Hamamoto‐Hardman BD, Steffey EP, McKemie DS, Kass PH, Knych HK. Meperidine pharmacokinetics and effects on physiologic parameters and thermal threshold following intravenous administration of three doses to horses. BMC Vet Res. 2020;16(1):368.
148. Knych HK, Weiner D, Arthur RM, Baden R, McKemie DS, Kass PH. Serum concentrations, pharmacokinetic/pharmacodynamic modeling, and effects of dexamethasone on inflammatory mediators following intravenous and oral administration to exercised horses. Drug Test Anal. 2020;12(8):1087‐1101.
149. Mercer MA, McKenzie HC, Davis JL, et al. Pharmacokinetics and safety of repeated oral dosing of acetaminophen in adult horses. Equine Vet J. 2020;52(1):120‐125.
150. Mercer MA, Davis JL, McKenzie HC, et al. Pharmacokinetics and efficacy of orally administered acetaminophen (paracetamol) in adult horses with experimentally induced endotoxemia. J Vet Intern Med. 2023;37(2):718‐727.
151. Mercer MA, McKenzie HC, Byron CR, et al. Pharmacokinetics and clinical efficacy of acetaminophen (paracetamol) in adult horses with mechanically induced lameness. Equine Vet J. 2023;55(3):524‐533.
152. Pesko B, Habershon‐Butcher J, Muir T, et al. Pharmacokinetics of paracetamol in the thoroughbred horse following an oral multi‐dose administration. J Vet Pharmacol Ther. 2022;45(1):54‐62.
153. Paine SW, Bright J, Scarth JP, et al. The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. J Vet Pharmacol Ther. 2020;43(2):162‐170.
154. Recchi L, Alvariza S, Benech A, et al. Pharmacokinetic study of oral amitriptyline in horses. J Vet Pharmacol Ther. 2020;43(4):381‐384.
155. Rostang A, Desjardins I, Espana B, et al. Pharmacokinetics of low‐dose methotrexate in horses. J Vet Pharmacol Ther. 2020;43(5):461‐469.
156. Tamura N, Okano A, Kuroda T, et al. Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration. Vet Ophthalmol. 2020;23(4):640‐647.
157. Wang J, Qiu J, Xiao H, et al. Pharmacokinetics of three formulations of vitacoxib in horses. J Vet Pharmacol Ther. 2020;43(4):364‐368.
158. Abu‐Basha EA, Bani IZ, Ababneh MM, Gehring R. Pharmacokinetics and bioavailability of tildipirosin following intravenous and subcutaneous administration in horses. J Vet Pharmaol Ther. 2021;44(4):544‐551. doi:10.1111/jvp.12958
159. Bousquet‐Mélou A, Schneider M, el Garch F, et al. Determination of the pharmacokinetic‐pharmacodynamic cut‐off values of marbofloxacin in horses to support the establishment of a clinical breakpoint for antimicrobial susceptibility testing. Equine Vet J. 2021;53(5):1047‐1055.
160. Gustafsson K, Tatz AJ, Dahan R, et al. Synovial concentration of trimethoprim‐sulphadiazine following regional limb perfusion in standing horses. Animals (Basel). 2021;11(7):2085.
161. Hess EK, Reinhart JM, Anderson MJ, Jannasch AS, Taylor SD. Pharmacokinetics of thiamine (vitamin B1) in adult horses after administration of three single intravenous doses. J Vet Pharmacol Ther. 2021;44(6):937‐944.
162. Knych HK, Arthur RM, McKemie DS, Baden RW, Seminoff K, Kass PH. Pharmacokinetics and anti‐inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised thoroughbred horses. Equine Vet J. 2021;53(1):102‐116.
163. Knych HK, Arthur RM, Gretler SR, McKemie DS, Goldin S, Kass PH. Pharmacokinetics of transdermal flunixin meglumine and effects on biomarkers of inflammation in horses. J Vet Pharmacol Ther. 2021;44(5):745‐753.
164. Kuroda T, Minamijima Y, Nomura M, et al. Medication control of flunixin in racing horses: possible detection times using Monte Carlo simulations. Equine Vet J. 2022;54(5):979‐988.
165. Knych HK, Magdesian KG. Equine antimicrobial therapy: current and past issues facing practitioners. J Vet Pharmacol Ther. 2021;44(2):270‐279.
166. Knych HK, Finno CJ, Baden R, Arthur RM, McKemie DS. Identification and characterization of the enzymes responsible for the metabolism of the non‐steroidal anti‐inflammatory drugs, flunixin meglumine and phenylbutazone, in horses. J Vet Pharmacol Ther. 2021;44(1):36‐46.
167. Kuroda T, Minamijima Y, Niwa H, et al. Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses. Equine Vet J. 2021;53(6):1239‐1249.
168. Leventhal HR, McKenzie HC, Estell K, Council‐Troche M, Davis JL. Pharmacokinetics and pulmonary distribution of Draxxin® (tulathromycin) in healthy adult horses. J Vet Pharmacol Ther. 2021;44(5):714‐723.
169. Neudeck S, Twele L, Kopp V, Kästner S. Pharmacodynamics and plasma concentrations of dexmedetomidine with or without vatinoxan as a constant‐rate infusion in horses anaesthetized with isoflurane‐a pilot study. J Vet Pharmacol Ther. 2021;44(5):754‐765.
170. Shane SE, Langston VC, Wills RW, et al. Pharmacokinetics and pharmacodynamics of intravenous continuous rate infusion and repeated intramuscular administration of dexmedetomidine in standing horses. J Vet Pharmacol Ther. 2021;44(4):533‐543.
171. O'Banion MP, Sundman E, Edmonds M, Davis J. Pharmacokinetics of dipyrone in horses: a multi‐dose, dose escalation study. J Vet Pharmacol Ther. 2021;44(6):919‐926.
172. Robinson MA, Stefanovski D, You Y, Boston RC, Soma LR. Bayesian‐based withdrawal estimates using pharmacokinetic parameters for two capsaicinoid‐containing products administered to horses. J Vet Pharmacol Ther. 2021;44(3):349‐358.
173. Ryan D, McKemie DS, Kass PH, Puschner B, Knych HK. Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses. Drug Test Anal. 2021;13(7):1305‐1317.
174. Sánchez de Medina A, Serrano‐Rodríguez JM, Díez de Castro E, et al. Pharmacokinetics and oral bioavailability of cannabidiol in horses after intravenous and oral administration with oil and micellar formulations. Equine Vet J. 2023;55(1094):1103. doi:10.1111/evj.13923
175. Schenk I, Machnik M, Broussou D, et al. Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: relevance for doping control. J Vet Pharmacol Ther. 2021;44(5):733‐744.
176. Waitt Wolker LH, Veltri CA, Pearman K, Lozoya M, Norris JW. Pharmacokinetics of fluoxetine in horses following oral administration. J Vet Pharmacol Ther. 2022;45(1):63‐68.
177. Wallace GE, McKaba VF, Reinhart JM, Li Z, Austin S, Fries RC. Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses. J Vet Pharmacol Ther. 2021;44(5):724‐732.
178. Wise JC, Hughes KJ, Edwards S, Jacobson GA, Narkowicz CK, Raidal SL. Pharmacokinetic and pharmacodynamic effects of 2 registered omeprazole preparations and varying dose rates in horses. J Vet Intern Med. 2020;35(1):620‐631.
179. Yılmaz İ, Maraş Z, Uğur Y, et al. Pharmacokinetic profiles of metamizole metabolites after intramuscular and intravenous administration in healthy Arabian horses. J Vet Pharmacol Ther. 2021;44(6):927‐936.
180. Adler DMT, Jorgensen E, Cornett C. The concentration of lidocaine and mepivacaine in synovial fluid of different joints after single intra‐articular injection. Front Vet Sci. 2022;9:1007399. doi:10.3389/fvets.2022.1007399
181. Hamamoto‐Hardman BD, Steffey EP, Seminoff K, McKemie DS, Kass P, Knych HK. Preliminary study of the pharmacokinetics, tissue distribution, and behavioural and select physiological effects of morphine 6‐glucuronide (M6G) following intravenous administration to horses. Can J Vet Res. 2022;86(3):172‐180.
182. Haughan JE, Missanelli JR, You Y, Stefanovski D, Soma LR, Robinson MA. Pharmacokinetics of glaucine after intravenous and oral administrations and detection of systemic aporphine alkaloids after ingestion of tulip poplar shavings in horses. J Vet Pharmacol Ther. 2022;45(3):273‐282.
183. Hunyadi L, Datta P, Rewers‐Felkins K, et al. Pharmacokinetics of a single dose of oclacitinib maleate as a top dress in adult horses. J Vet Pharmacol Ther. 2022;45(3):320‐324.
184. Ishii H, Leung GN, Yamashita S, et al. Comprehensive metabolic study of nicotine in equine plasma and urine using liquid chromatography/high‐resolution mass spectrometry for the identification of unique biomarkers for doping control. J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1190:123100.
185. Ishii H, Shibuya M, Leung GN, et al. Additional studies on nicotine exposure in horses: accurate quantification and elimination profiles of potential biomarkers in plasma and urine. Rapid Commun Mass Spectrom. 2022;36(23):e9396.
186. Knych HK, Weiner D, Harrison L, McKemie DS. Pharmacokinetics and pharmacodynamics of intra‐articular isoflupredone following administration to horses with lipopolysaccharide‐induced synovitis. BMC Vet Res. 2022;18(1):436.
187. Luethy D, Robinson MA, Stefanovski D, et al. Pharmacokinetics and pharmacodynamics of oral and intravenous metoprolol tartrate in clinically healthy horses. J Vet Pharmacol Ther. 2022;45(2):177‐187.
188. Minuto J, Bedenice D, Ceresia M, Zaghloul I, Böhlke M, Mazan MR. Clinical effects and pharmacokinetics of nebulized lidocaine in healthy horses. Front Vet Sci. 2022;9:984108.
189. Redmond JS, Stang BV, Schlipf JW Jr, Christensen JM. Pharmacokinetics of diphenhydramine following single‐dose intravenous and oral administration in non‐fasted adult horses. J Vet Pharmacol Ther. 2022;45(2):188‐195.
190. Rhodin M, Haubro AP, Holm FK, Ekstrand C. In vivo joint synovial fluid disposition of a novel sustained‐release formulation of diclofenac and hyaluronic acid in horses. J Vet Pharmacol Ther. 2021;45(2):167‐176.
191. Skrzypczak H, Reed R, Brainard B, et al. The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. Equine Vet J. 2022;54(1):153‐158.
192. Fadel C, Giorgi M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses. Vet Anim Sci. 2023;19:100286.
193. Kuroda T, Minamijima Y, Mita H, et al. Rational determination of cefazolin dosage regimen in horses based on pharmacokinetics/pharmacodynamics principles and Monte Carlo simulations. J Vet Pharmacol Ther. 2023;46(1):62‐67.
194. Maxwell L, McCarrel TM, Hay S, Cole C. Pharmacokinetics of aminocaproic acid in thoroughbred horses. J Vet Pharmacol Ther. 2023;46(3):250‐256.
195. Schenk I, Broussou D, Roques B, et al. Control of a sulfadoxine/trimethoprim combination in the competition horse: elimination, metabolism and detection following an intravenous administration. Drug Test Anal. 2023;15(6):629‐645.
196. di Cesare F, Negro V, Ravasio G, Villa R, Draghi S, Cagnardi P. Gabapentin: clinical use and pharmacokinetics in dogs, cats, and horses. Animals (Basel). 2023;13(12):2045.
197. Tueshaus T, McKemie DS, Kanarr K, Kass PH, Knych HK. Pharmacokinetics and effects of codeine in combination with acetaminophen on thermal nociception in horses. J Vet Pharmacol Ther. 2023;46(5):311‐325.
198. Knych HK, McKemie DS, Kass PH, Stanley SD, Blea J. Ketoprofen in horses: metabolism, pharmacokinetics, and effects on inflammatory biomarkers. Drug Test Anal. 2023;16(3):289‐302.
199. Paine SW, Harding C, Waller CC, et al. Novel holistic pharmacokinetic model applied to plasma and urine concentrations of 2,5‐dihydroxybenzene sulphonate following administrations of calcium dobesilate and etamsylate to exercised horses. J Vet Pharmacol Ther May. Epub ahead of print. 2023;46(6):365‐374. doi:10.1111/jvp.13387
200. Mercer MA, Davis JL, McKenzie HC. The clinical pharmacology and therapeutic evaluation of non‐steroidal anti‐inflammatory drugs in adult horses. Animals (Basel). 2023;13(10):1597.
201. Rivera‐Velez SM, Navas J, Villarino NF. Applying metabolomics to veterinary pharmacology and therapeutics. J Vet Pharmacol Ther. 2021;44(6):855‐869.
202. Viljanto MJ, Kicman AT, Walker CJ, et al. Elucidation of the biosynthetic pathways of boldenone in the equine testis. Steroids. 2019;146:79‐91.
203. Viljanto M, Kicman AT, Walker CJ, et al. Bioformation of boldenone and related precursors/metabolites in equine faeces and urine, with relevance to doping control. Drug Test Anal. 2020;12(2):215‐229.
204. Viljanto M, Kaabia Z, Taylor P, et al. Differentiation of boldenone administration from ex vivo transformation in the urine of castrated male horses. Drug Test Anal. 2022;14(5):887‐901.
205. Viljanto M, Kaabia Z, Taylor P, et al. Detection of boldenone in the urine of female horses‐ex vivo formation versus administration. Drug Test Anal. 2024;16(2):112‐126.
206. Legacki EL, Scholtz EL, Ball BA, Esteller‐Vico A, Stanley SD, Conley AJ. Concentrations of sulphated estrone, estradiol and dehydroepiandrosterone measured by mass spectrometry in pregnant mares. Equine Vet J. 2019;51(6):802‐808.
207. Viljanto M, Hincks P, Hillyer L, et al. Monitoring dehydroepiandrosterone (DHEA) in the urine of thoroughbred geldings for doping control purposes. Drug Test Anal. 2018;10(10):1518‐1527.
208. Dirikolu L, Lehner AF. A review of current chemistry, pharmacology, and regulation of endogenous anabolic steroids testosterone, boldenone, and nandrolone in horses. J Vet Pharmacol Ther. 2023;46(4):201‐217.
209. Habib H, Finno CJ, Gennity I, et al. Simultaneous quantification of vitamin E and vitamin E metabolites in equine plasma and serum using LC‐MS/MS. J Vet Diagn Invest. 2021;33(3):506‐515.
210. Favro G, Habib H, Gennity I, et al. Determination of vitamin E and its metabolites in equine urine using liquid chromatography‐mass spectrometry. Drug Test Anal. 2021;13(6):1158‐1168.
211. Tavanaeimanesh H, Dashli‐Boroon OJ, Corley K. Comparison of β‐endorphin, lactate and cortisol concentrations in winning and losing racehorses. J Equine Vet. 2022;110:103857.
212. Tou K, Cawley A, Bowen C, Sornalingam K, Fu S. Measurements of hydrocortisone and cortisone for longitudinal profiling of equine plasma by liquid chromatography‐tandem mass spectrometry. Drug Test Anal. 2022;14(5):943‐952.
213. Guan F, You Y, Li X, Robinson MA. A comprehensive approach to detecting multitudinous bioactive peptides in equine plasma and urine using hydrophilic interaction liquid chromatography coupled to high resolution mass spectrometry. Drug Test Anal. 2019;11(9):1308‐1325.
214. Guan F, Fay S, Li X, You Y, Robinson MA. Identification of ex vivo catabolites of peptides with doping potential in equine plasma by HILIC‐HRMS. Drug Test Anal. 2020;12(6):771‐784.
215. Kwok KY, Choi TLS, Kwok WH, et al. Detection of bioactive peptides including gonadotrophin‐releasing factors (GnRHs) in horse urine using ultra‐high performance liquid chromatography‐high resolution mass spectrometry (UHPLC/HRMS). Drug Test Anal. 2020;12(9):1274‐1286.
216. Flores L, Hargrave S, Clifford A, Alarcio G, Moeller BC. Detection of doping peptides and basic drugs in equine urine using liquid chromatography‐mass spectrometry. Drug Test Anal. 2024;16(4):406‐419.
217. Pinetre J, Delcourt V, Becher F, et al. High‐throughput untargeted screening of biotherapeutic macromolecules in equine plasma by UHPLC‐HRMS/MS: application to monoclonal antibodies and fc‐fusion proteins for doping control. Drug Test Anal. 2024;16(2):199‐209.
218. Gómez‐Guerrero NA, González‐López NM, Zapata‐Velásquez JD, Martínez‐Ramírez JA, Rivera‐Monroy ZJ, García‐Castañeda JE. Synthetic peptides in doping control: a powerful tool for an analytical challenge. ACS Omega. 2022;7(43):38193‐38206.
219. Cavalcanti RTC, Teixeira PAC, Levy RS, Pereira HMG, Aquino Neto FR. Detection of ESAs in equine urine and blood by SAR‐PAGE. Drug Test Anal. 2019;11(6):772‐781.
220. Timms M, Ganio K, Forbes G, Bailey S, Steel R. An immuno polymerase chain reaction screen for the detection of CJC‐1295 and other growth‐hormone‐releasing hormone analogs in equine plasma. Drug Test Anal. 2019;11(6):804‐812.
221. Timms M, Ganio K, Steel R. A method for confirming CJC‐1295 abuse in equine plasma samples by LC‐MS/MS. Drug Test Anal. 2019;11(8):1248‐1257.
222. Kwok WH, Choi TLS, Leung GNW, et al. Administration study of recombinant human relaxin‐2 in horse for doping control purpose. Drug Test Anal. 2020;12(3):361‐370.
223. Delcourt V, Garcia P, Chabot B, et al. TB500/TB1000 and SGF1000: a scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458‐464.
224. Timms M, Ganio K, Steel R. Extraction of α‐neurotoxins from equine plasma by receptor based affinity purification. Drug Test Anal. 2020;12(7):918‐928.
225. Choi TLS, Lau MY, Wong JKY, Wan TSM, Ho ENM. Identification of the dermorphin tetrapeptide [Dmt1]‐DALDA in a seized unlabelled vial and its first detection in horse urine: a case report. Drug Test Anal. 2024;16(3):268‐276.
226. Wong KS, Cheung HW, Choi YC, To NS, Wan TSM, Ho ENM. Screening and confirmation of recombinant human follistatin in equine plasma for doping control purposes. Drug Test Anal. 2023;16:259‐267. doi:10.1002/dta.3540
227. Timms M, Botteon A, Manos C, Griffin J, Levina V, Steel R. Detection of gonadotropin‐releasing hormone and its analogues in equine and canine urine by high‐resolution data‐independent acquisition. Drug Test Anal. 2023;15(8):896‐908.
228. So YM, Wong JKY, Wong ASY, Tse ATL, Wan TSM, Ho ENM. Identification of erythropoietin mimetic peptide 1 linear form in a sealed vial and its administration study in horses for doping control purpose. Drug Test Anal. 2024;16(1):71‐82.
229. Timms M, Steel R. Defining the specificity of recombinant human erythropoietin confirmation in equine samples by liquid chromatography‐tandem mass spectrometry. Drug Test Anal. 2022;14(4):676‐689.
230. Keen B, Cawley A, Reedy B, Fu S. Metabolomics in clinical and forensic toxicology, sports anti‐doping and veterinary residues. Drug Test Anal. 2022;14(5):794‐807.
231. Tou K, Cawley A, Bowen C, Bishop DP, Fu S. Towards non‐targeted screening of lipid biomarkers for improved equine anti‐doping. Molecules. 2022;28(1):312.
232. Cawley A, Keen B, Tou K, Elbourne M, Keledjian J. Biomarker ratios. Drug Test Anal. 2022;14(5):983‐990.
233. Stojiljkovic N, Leroux F, Bubanj S, et al. Tracking main environmental factors masking a minor steroidal doping effect using metabolomic analysis of horse urine by liquid chromatography‐high‐resolution mass spectrometry. Eur J Mass Spectrom. 2019;25(3):339‐353.
234. Ueda T, Tozaki T, Nozawa S, Kinoshita K, Gawahara H. Identification of metabolomic changes in horse plasma after racing by liquid chromatography‐high resolution mass spectrometry as a strategy for doping testing. J Equine Sci. 2019;30(3):55‐61.
235. Ohnuma K, Uchida T, Leung GN, Ueda T, Obara T, Ishii H. Establishment of a post‐race biomarkers database and application of pathway analysis to identify potential biomarkers in post‐race equine plasma. Drug Test Anal. 2022;14(5):915‐928.
236. Cloteau C, Dervilly G, Kaabia Z, et al. From a non‐targeted metabolomics approach to a targeted biomarkers strategy to highlight testosterone abuse in equine. Illustration of a methodological transfer between platforms and laboratories. Drug Test Anal. 2022;14(5):864‐878.
237. Cloteau C, Dervilly G, Loup B, et al. Performance assessment of an equine metabolomics model for screening a range of anabolic agents. Metabolomics. 2023;19(4):38.
238. Cheung HW, Wong KS, To NS, et al. Label‐free proteomics for discovering biomarker candidates of RAD140 administration to castrated horses. Drug Test Anal. 2021;13(5):1034‐1047.
239. Ishii H, Leung GN, Yamashita S, et al. Identification of potential biomarkers in urine and plasma after consumption of tobacco product in horses. Drug Test Anal. 2022;14(5):902‐914.
240. Wong KS, Cheung HW, Choi TLS, et al. Label‐free proteomics for discovering biomarker candidates for controlling krypton misuse in castrated horses (geldings). J Proteome Res. 2020;19(3):1196‐1208.
241. Keen B, Cawley A, Fouracre C, Pyke J, Fu S. Towards an untargeted mass spectrometric approach for improved screening in equine antidoping. Drug Test Anal. 2021;13(5):1001‐1007.
242. Burns LE, Borts DJ. Rapid untargeted screening for drug residues in animal tissues with liquid microjunction surface sampling probe mass spectrometry. Anal Chim Acta. 2019;1063:75‐78.
243. Guan F, Fay S, Adreance MA, et al. Automated identification of unknown doping agents in confiscation samples by flow‐injection mass spectrometry and mass spectral library searches. Drug Test Anal. 2023;15(7):779‐786.
244. Leung DKK, Wong ASY, Zhou QL, Wan TSM, Ho ENM. Application of a non‐target variable data independent workflow (vDIA) for the screening of prohibited substances in doping control testing. Drug Test Anal. 2021;13(5):1008‐1033.
245. You Y, Proctor RM, Guo K, et al. Use of high resolution/accurate mass full scan/data‐dependent acquisition for targeted/non‐targeted screening in equine doping control. Anal Methods. 2021;13(13):1565‐1575.
246. Klingberg J, Cawley A, Shimmon R, Fouracre C, Pasin D, Fu S. Finding the proverbial needle: non‐targeted screening of synthetic opioids in equine plasma. Drug Test Anal. 2021;13(5):977‐989.
247. Guan F, You Y, Fay S, Li X, Robinson MA. Novel algorithms for comprehensive untargeted detection of doping agents in biological samples. Anal Chem. 2021;93(21):7746‐7753.
248. Guan F, You Y, Fay S, Adreance MA, McGoldrick LK, Robinson MA. Factors affecting untargeted detection of doping agents in biological samples. Talanta. 2023;258:124446.
249. Ishii H, Shibuya M, Kusano K, et al. Generic approach for the discovery of drug metabolites in horses based on data‐dependent acquisition by liquid chromatography high‐resolution mass spectrometry and its applications to pharmacokinetic study of daprodustat. Anal Bioanal Chem. 2022;414(28):8125‐8142. doi:10.1007/s00216‐022‐04347‐2
250. Barnabé A, Moulard Y, Trevisiol S, et al. Kavain detection in post‐race equine urine sample: A case report. Drug Test Anal. 2021;13(4):883‐886.
251. Francis KA, Tkachenko A, Johnson JT, et al. Comprehensive evaluation of HPLC‐MS/MS method for quantitation of seven anticoagulant rodenticides and dicoumarol in animal serum. J Anal Toxicol. 2023;47(5):429‐435.
252. Göktaş EF, Kabil E, Arıöz F. Quantification and validation of nine nonsteroidal anti‐inflammatory drugs in equine urine using gas chromatography‐mass spectrometry for doping control. Drug Test Anal. 2020;12(8):1065‐1077.
253. Göktaş EF, Kabil E, Yatanaslan L, Güneş E, Dirikolu L. Simultaneous quantification of caffeine and its main metabolites by gas chromatography mass spectrometry in horse urine. Biomed Chromatogr. 2022;36(10):e5445.
254. Ishii H, Obara T, Kijima‐Suda I. Investigation of plasma concentrations of paracetamol, metacetamol, and orthocetamol in Japanese racehorses using liquid chromatography‐electrospray ionisation‐tandem mass spectrometry. Drug Test Anal. 2020;12(7):929‐937.
255. Ishii H, Obara T, Kusano K, Kijima‐Suda I. Quantitative analysis of paracetamol, metacetamol, and orthocetamol in equine urine from racehorses in Japan using liquid chromatography‐electrospray ionization‐tandem mass spectrometry. Drug Test Anal. 2020;12(8):1196‐1202.
256. Johnson E, van Heemst J, Benavides J, Gray B. Metabolism and excretion of the benzodiazepine analogue etizolam in the horse. Drug Test Anal. 2020;13(3):583‐594.
257. Kabil E, Göktaş EF, Güneş E, et al. Cocktail drug usage and etofenamate detection in post‐race equine urine sample: a case report. Biomed Chromatogr. 2023;37(3):e5556.
258. Karakka Kal AK, Karatt TK, Sayed R, Philip M, Meissir S, Nalakath J. Separation of ephedrine and pseudoephedrine enantiomers using a polysaccharide‐based chiral column: a normal phase liquid chromatography‐high‐resolution mass spectrometry approach. Chirality. 2019;31(8):568‐574.
259. Elbourne M, Cawley A, Stanley S, Bowen C, Fu S. Intelligence benefit of the 3‐methoxytyramine to tyramine ratio in equine urine. Drug Test Anal. 2022;14(5):936‐942.
260. Keen B, Cawley A, Reedy B, Noble G, Loy J, Fu S. 3‐Methoxytyrosine as an indicator of dopaminergic manipulation in equine plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2023;1220:123652.
261. Knych HK, Mama KR, Moore CE, Hill AE, McKemie DS. Plasma and synovial fluid concentrations and cartilage toxicity of bupivacaine following intra‐articular administration of a liposomal formulation to horses. Equine Vet J. 2019;51(3):408‐414.
262. Kusano K, Minamijima Y, Mashita S, Kunii H, Yamashita S, Nagata S. Concentrations of indomethacin and its metabolite desmethylindomethacin in plasma and urine after repeated indomethacin topical application to thoroughbreds. Equine Vet J. 2019;51(4):506‐509.
263. Loganathan D, Yi R, Patel B, Zhang J, Kong N. A sensitive HPLC‐MS/MS method for the detection, resolution and quantitation of cathinone enantiomers in horse blood plasma and urine. Anal Bioanal Chem. 2021;413(8):2147‐2161. doi:10.1007/s00216‐021‐03182‐1
264. Mizobe F, Mori M, Nagata SI, Yamashita S, Okada J, Kusano K. Presence of antimicrobials in postrace samples in Japanese thoroughbred racing. J Equine Vet. 2020;91:103115.
265. Philip M, Karakka Kal AK, Subhahar MB, et al. Hydroxy levamisole and its phase II conjugates as potential indicators of levamisole doping in thoroughbred horses. Rapid Commun Mass Spectrom. 2023;37(3):e9430.
266. Stanley S, Deng D, van den Berg K, Foo HC. The equine metabolism of the catechol‐O‐methyltransferase enzyme inhibitor nitecapone. Drug Test Anal. 2022;14(5):929‐935.
267. Waraksa E, Woźniak MK, Kłodzińska E, Wrzesień R, Bobrowska‐Korczak B, Namieśnik J. A rapid and sensitive method for the quantitative analysis of ibuprofen and its metabolites in equine urine samples by gas chromatography with tandem mass spectrometry. J Sep Sci. 2018;41(20):3881‐3891.
268. Waraksa E, Owczarek K, Kubica P, et al. Determination of bromhexine and its metabolites in equine serum samples by liquid chromatography‐tandem mass spectrometry: applicability to the elimination study after single oral dose. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1151:122197.
269. Wong ASY, Choi TLS, Kwok KY, Wong JKY, Wan TSM, Ho ENM. Doping control analysis of antipsychotics and other prohibited substances in equine plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1147:122132.
270. You Y, Proctor RM, Vasilko ED, Robinson MA. Doping control analysis of four JWH‐250 metabolites in equine urine by liquid chromatography‐tandem mass spectrometry. Drug Test Anal. 2018;11(5):649‐658.
271. You Y, Guan F, D'Ippolito R, Li X, Soma LR, Robinson MA. High‐throughput doping control analysis of 28 amphetamine‐type stimulants in equine plasma using hydrophilic interaction liquid chromatography‐tandem mass spectrometry. Drug Test Anal. 2019;11(3):441‐454.
272. You Y, Proctor RM, Haughan J, Missanelli JR, Robinson MA. Use of liquid chromatography–tandem mass spectrometry to quantify and confirm the fentanyl metabolite N‐[1‐(2‐Phenethy‐4‐Piperidinyl)] Maloanilinic acid in equine urine for doping control. J Anal Toxicol. 2023;47(4):393‐402.
273. Zak A, Siwinska N, Slowikowska M, et al. The detection of capsaicin and dihydrocapsaicin in horse serum following long‐term local administration. BMC Vet Res. 2018;14(1):193.
274. Kwak YB, Choi MS. Identification of a metabolite for the detection of the hydrophilic drug diisopropylamine for doping control. J Pharm Biomed Anal. 2023;234:115576.
275. Stanley S, van den Berg K, Foo HC, Deng D. Metabolism and elimination of the catechol‐o‐methyltransferase inhibitor tolcapone in the horse. Drug Test Anal. 2019;11(4):578‐585.
276. Machin J, Childers T, Kudrimoti S, et al. Synthesis and characterization of barbarin, a possible source of unexplained aminorex identifications in forensic science. Drug Test Anal. 2020;12(10):1477‐1482.
277. Kudrimoti S, Machin J, Arojojoye AS, et al. Synthesis and characterization of d5‐barbarin for use in barbarin‐related research. Drug Test Anal. 2023;15(1):42‐46.
278. Wong JKY, Chan GHM, Choi TLS, et al. A high‐throughput and broad‐spectrum screening method for analysing over 120 drugs in horse urine using liquid chromatography‐high‐resolution mass spectrometry. Drug Test Anal. 2020;12(7):900‐917.
279. Chen Q, Wang Z, Chen H. A hydrophobic deep eutectic solvent‐based vortex‐assisted liquid‐liquid microextraction applied for doping control of aromatase inhibitors from equine urine. J Pharm Biomed Anal. 2023;234:115583.
280. Waller P, Lomnicka I, Lucas C, Johnson S, Dirikolu L. The medication violations in racehorses at Louisiana racetracks from 2016 to 2020. Vet Med Sci. 2022;8(2):553‐560.
281. Rooney MF, Neto NGB, Monaghan MG, Hill EW, Porter RK. Conditionally immortalised equine skeletal muscle cell lines for in vitro analysis. Biochem Biophys Rep. 2022;33:101391.
282. Moreira F, Carmo H, Guedes de Pinho P, Bastos ML. Doping detection in animals: a review of analytical methodologies published from 1990 to 2019. Drug Test Anal. 2021;13(3):474‐504.
283. Lee W, Ko BJ, Sim YE, Suh S, Yoon D, Kim S. Discrimination of human urine from animal urine using 1H‐NMR. J Anal Toxicol. 2019;43(1):51‐60.
284. Trevorrow P. Ile de Chypre—nobbles, jinks, and the ultrasonic sniper. Drug Test Anal. 2020;12(5):651‐652.
285. Garcia P, Pinètre J, Morel S, et al. An innovative derivatization‐free IC‐MS/MS method for the detection of bisphosphonates in horse plasma. Drug Test Anal. 2020;12(10):1452‐1461.
286. Garcia P, Perot I, Loup B, et al. Long‐term detection of clodronate in equine plasma by liquid chromatography‐tandem mass spectrometry. Drug Test Anal. 2021;13(8):1527‐1534.
287. Riggs CM, Thompson SL, So YM, et al. Tiludronic acid can be detected in blood and urine samples from thoroughbred racehorses over 3 years after last administration. Equine Vet J. 2021;53(6):1287‐1295.
288. Krueger CR, Mitchell CF, Leise BS, Knych HK. Pharmacokinetics and pharmacodynamics of clodronate disodium evaluated in plasma, synovial fluid and urine. Equine Vet J. 2020;52(5):725‐732.
289. Knych HK, Janes J, Kennedy L, et al. Detection and residence time of bisphosphonates in bone of horses. J Vet Diagn Invest. 2022;34(1):23‐27.
290. Knych HK, Finno CJ, Katzman S, et al. Clodronate detection and effects on markers of bone resorption are prolonged following a single administration to horses. Equine Vet J. 2023;55(4):696‐706.
291. Bailey SR, Forbes G, Selvadurai N, McLarney K, Jones S, Steel CM. The effect of serial administration of bicarbonate on plasma total CO2 concentrations in horses. Drug Test Anal. 2021;13(2):397‐403.
292. Dirikolu L, Waller P, Malveaux K, et al. Total carbon dioxide (TCO2) concentrations in thoroughbred and quarter racehorses in Louisiana. J Equine Vet. 2023;121:104220.
293. LMI. Total carbon dioxide in adult standardbred and thoroughbred horses. J Equine Vet. 2021;106:103730. doi:10.1016/j.jevs.2021.103730
294. Zahra PW, Jayasinghe NS, Selvadurai NS, et al. A fully automated method to quantitate total carbon dioxide in equine plasma by headspace GCMS. Drug Test Anal. 2022;14(10):1724‐1731.
295. Hertzsch R, Richter A. Systematic analysis to assess the scientific validity of the international residue limits for caffeine and theophylline in horse‐racing. Vet Rec. 2019;185(8):230.
296. Hertzsch R. Anti‐doping‐Regeln im Pferdesport und pharmakologische Aspekte der regelkonformen Therapie und Fütterung von Sportpferden [Antidoping rules in equine sports and pharmacological aspects of rule‐consistent medical treatment and feeding of sport horses]. Tierarztl Prax Ausg G Grosstiere Nutztiere. 2020;48(2):106‐117.
297. Ammer H. Challenging the international residue limit concept for feed contaminants in equine doping analytics. Vet Rec. 2019;185(8):227‐229.
298. Brewer K, Machin JJ, Maylin G, et al. Case report: synephrine, a plant substance yielding classic environmental clusters of hay related identifications in equine urine. Drug Test Anal. 2022;14(4):774‐780.
299. Maylin G, Fenger C, Machin J, et al. Aminorex identified in horse urine following consumption of Barbera vulgaris; a preliminary report. Ir Vet J. 2019;2019(15):75. doi:10.1186/s13620‐019‐0153‐5
300. Machin J, Brewer K, Morales‐Briceno A, Fenger C, Maylin G, Tobin T. Sporadic worldwide “clusters” of feed driven Zilpaterol identifications in racing horses: a review and analysis. Ir Vet J. 2022;75(1):11.
301. Machin J, Brewer K, Catignani M, et al. An interim screening limit of detection for naproxen in equine plasma: a review and analysis. Comp Exercise Physiology. 2020;16(2):153‐160.
302. Brewer K, Machin JJ, Maylin G, Fenger C, Morales‐Briceño A, Tobin T. Gabapentin, a human therapeutic medication and an environmental substance transferring at trace levels to horses: a case report. Ir Vet J. 2022;19:75.
303. Thevis M, Kuuranne T, Geyer H. Annual banned‐substance review: analytical approaches in human sports drug testing. Drug Test Anal. 2019;11(1):8‐26.
304. Thevis M, Kuuranne T, Geyer H. Annual banned‐substance review—analytical approaches in human sports drug testing. Drug Test Anal. 2020;12(1):7‐26.
305. Thevis M, Kuuranne T, Geyer H. Annual banned‐substance review: analytical approaches in human sports drug testing 2019/2020. Drug Test Anal. 2021;13(1):8‐35.
306. Thevis M, Kuuranne T, Geyer H. Annual banned‐substance review: analytical approaches in human sports drug testing 2020/2021. Drug Test Anal. 2022;14(1):7‐30. doi:10.1002/dta.3199
307. Thevis M, Kuuranne T, Geyer H. Annual banned‐substance review: analytical approaches in human sports drug testing 2021/2022. Drug Test Anal. 2023;15(1):5‐26.
308. European Monitoring Centre for Drugs and Drug Addiction – European Drug Report 2023: Trends and Developments. www.emcdda.europa.eu Accessed 6th September 2023.
309. British Horseracing Authority written evidence, 2020. Accessed 12th July 2023. https://committees.parliment.uk/writtenevidence/7020/pdf/
310. Paulick Report. Truesdail Lab Sees RMTC Accreditation Suspended ‐ Paulick Report | Shining Light on the Horse Industry. Accessed 6th June 2024.
311. Thoroughbred Daily News. RMTC Extends Suspension of UK Lab's Accreditation Another Six Months (thoroughbreddailynews.com). Accessed 6th June 2024.
312. Paulick Report. Louisiana Commission Selects HISA‐Approved Industrial Laboratories To Serve As Interim State Chemist ‐ Paulick Report | Shining Light on the Horse Industry. Accessed 6th June 2024.

Citations